Tag: AXIM biotech

June 23, 2017

AXIM Biotech Applies for US Patent on Opioid Addiction Treatment

AXIM Biotechnologies applied for a patent with the United States Patent and Trademark Office involving a chewing gum composition with...
January 18, 2017

AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum

AXIM® Biotechnologies (OTC:AXIM), a world leader in cannabinoid research and development, entered a clinical trial on treating irritable bowel syndrome...
January 4, 2017

AXIM® Biotech Receives Positive PK Data Results for CanChew Plus® CBD Gum

AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, received positive pharmacokinetic (PK) data results...
December 6, 2016

AXIM® Biotech Receives Medical Ethical Committee Approval to Begin IBS Trial for Canchew Plus® CBDGum

AXIM® Biotechnologies today announced that it received approval from the Medical Ethical Committee of Wageningen University, The Netherlands, to begin...
November 3, 2016

Medical Marijuana Publishes Product Pipeline Chart for Pharma Clinical Trials Program

Medical Marijuana, Inc. (OTC: MJNA) today announced that its investment AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader...
November 1, 2016

AXIM Biotech Begins PK/PD Studies With CanChew Plus CBD Gum for IBS Symptoms

AXIM® Biotechnologies, a world leader in cannabinoid research and development, today announced that it has begun pharmacokinetic/pharmacodynamics studies with its...
October 6, 2016

AXIM Biotechnologies CEO to Speak at National Symposium on Medical Cannabis in Mexico City

AXIM® Biotechnologies (OTC:AXIM) announced that its Chief Executive Officer, George E. Anastassov, MD, DDS, MBA, will speak at the First...